Viela Bio, Inc. announced unaudited financial results for the third quarter and nine months ended September 30, 2020. For the quarter, Total revenue was $2,316,000. Loss from operations was $38,219,000 against $48,930,000 a year ago. Net loss was $37,645,000 against $48,410,000 a year ago. Net loss per share attributable to common stockholders—basic and diluted was $0.69 against $64.59 a year ago. For the nine months, Total revenue was $2,316,000 against $20,000,000 a year ago. Loss from operations was $120,150,000 against $76,688,000 a year ago. Net loss was $117,279,000 against $78,859,000 a year ago. Net loss per share attributable to common stockholders—basic and diluted was $2.23 against $150.34 a year ago.